Mezigdomide通过降解IKZF1/IKZF3逆转T细胞耗竭并恢复细胞因子产生通路
本研究探讨mezigdomide靶向IKZF1/IKZF3能否逆转多发性骨髓瘤中T细胞耗竭。对体外生成的耗竭T细胞进行转录组和表观遗传分析发现,IKZF1/IKZF3直接结合耗竭基因和细胞因子基因的启动子与增强子调控转录。Mezigdomide处理降低耗竭标志物表达、增加促炎细胞因子表达,并增强alnuctamab对靶细胞的杀伤。
要点
- IKZF1/IKZF3是T细胞耗竭发生与维持的关键调控因子
- Mezigdomide处理降低耗竭标志物并增加促炎细胞因子表达
- Mezigdomide增强BCMA靶向TCE药物alnuctamab的靶细胞杀伤
核心结论
- 靶向IKZF1/IKZF3可逆转T细胞耗竭并恢复功能,支持mezigdomide联合TCE治疗MM的合理性。
研究设计与样本
- 对体外生成的耗竭T细胞及其自体活化T细胞进行转录组和表观遗传学分析。
- 使用mezigdomide处理耗竭T细胞,评估耗竭标志物、细胞因子表达及alnuctamab介导的靶细胞杀伤。
主要发现
- IKZF1和IKZF3通过直接结合启动子和增强子(近端和远端)调控转录,改变转录潜能。
- 多次T细胞刺激后IKZF1与耗竭基因结合增加增强其转录,与细胞因子基因结合则抑制转录。
- Mezigdomide处理耗竭T细胞后耗竭相关标志物表达下降、促炎细胞因子表达升高。
- Mezigdomide增强alnuctamab(BCMA靶向TCE)对靶细胞的杀伤。
临床怎么用
- Mezigdomide联合TCE(如alnuctamab)可能增强MM治疗疗效,为克服TCE耐药提供策略。
局限性
- 研究基于体外生成的耗竭T细胞,未在体内或临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell exhaustion has been shown to be a key resistance mechanism to efficacy of T-cell engagers (TCE) in multiple myeloma (MM). Mezigdomide, a potent cereblon E3 ligase modulator that targets IKZF1 and IKZF3 simultaneously for proteasomal degradation, has been shown to modulate T-cell activity in patients with MM. We explored the possibility that targeting IKZF1/IKZF3 could address T-cell exhaustion and restore functionality. We conducted extensive transcriptomic and epigenetic profiling on ex vivo generated exhausted T cells (Tex), using their autologous activated T cells as a comparison. Our study revealed that IKZF1 and IKZF3 are critical regulators that contribute to the development and maintenance of T-cell exhaustion. They regulate transcription by directly binding to promoters and enhancers, both proximal and distal, thereby altering transcriptional potential. Increased IKZF1 binding to exhaustion genes after multiple T-cell stimulations results in the enhancement of transcription, whereas binding to cytokine genes results in transcription repression. Mezigdomide treatment in Tex results in decreased expression of exhaustion-related markers, increased proinflammatory cytokine expression, and enhanced target cell killing with alnuctamab, a B-cell maturation antigen targeting TCE. This study provides crucial mechanistic insights into the roles of IKZF1/IKZF3 in T-cell exhaustion, supporting the rationale for combining mezigdomide with TCE to enhance therapeutic outcomes in MM.
引用
- Chiu H, Zhao J, Basavanhally T, et al. Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways. Blood. 2026. PMID: 42118707. doi:10.1182/blood.2025030873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。